AbCellera Biologics Inc. Common Shares (ABCL) Dividend History

Company News

• Down 57%, Is AbCellera Biologics a Buy on the Dip?

  Wall Street analysts say this drug developer can more than double your money.

  The Motley Fool

  Featured Companies: LLY
• AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript

  ABCL earnings call for the period ending March 31, 2024.

  The Motley Fool
• AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates

  AbCellera Biologics (ABCL) delivered earnings and revenue surprises of 12.50% and 11.64%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: RNA
• Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

  Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  Zacks Investment Research

  Featured Companies: CYTK
• Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for

  AbCellera Biologics (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  Zacks Investment Research

  Featured Companies: ILMN